Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine efficacy surveillance for uncomplicated falciparum malaria in Papua New Guinea
ACTRN12617000664347Phase 4Not yet recruiting
- Sponsor
- United States Department of Health and Human Services
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether + lumefantrine in malaria and Falciparum malaria (PF), sponsored by United States Department of Health and Human Services. Primary endpoints: Percent of treatment failures and Adequate clinical and parasitological response. Planned start May 2017; status: not yet recruiting.
02
Drugs
artemether + lumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12617000664347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000664347.